RxDoctor Payments Data

Glenn Graves, MD

Glaucoma Specialist · Greenfield, WINPI 1780671677

Payments from drug & device makers

$688in general payments, 2019–2025

Across 37 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$242
  • NEW World Medical,inc.$218
  • Alcon$57
  • The Cameron-ehlen Group, Inc.$47
  • Sight Sciences, Inc.$38
  • Thea Pharma Inc.$25
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$66697%
  • Education$223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)9$242
NEW World Medical,inc.17$218
Alcon3$57
The Cameron-ehlen Group, Inc.1$47
Sight Sciences, Inc.2$38
Thea Pharma Inc.1$25
Glaukos Corporation1$23
Bausch & Lomb, A Division Of Bausch Health US, LLC2$22
Rxsight Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$169,853
Medicare patients
610
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost249$150,570
RestasisCyclosporine58$45,065
LumiganBimatoprost73$39,042
VyzultaLatanoprostene Bunod42$22,276
SimbrinzaBrinzolamide/Brimonidine Tart65$21,549
RhopressaNetarsudil Mesylate35$18,863
CombiganBrimonidine Tartrate/Timolol51$18,328
Cyclosporine16$17,823
Latanoprost1,416$16,127
Alphagan PBrimonidine Tartrate39$13,507
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol94$13,027
Dorzolamide-TimololDorzolamide/Timolol/Pf34$9,118
Travoprost62$7,190
Brimonidine Tartrate48$4,874
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat338$4,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$242$115,942221 claims
AlconSimbrinza$57$21,54965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Greenfield

Where these figures come from

Is this you, or does something look wrong? →